Physician profile
Mark J Silversmith
NPI 1104825587
$5,713.93
in general payments reported to CMS, 2019-2025
23 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $714 · 2021: $796 · 2022: $523 · 2023: $869 · 2024: $819 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,908.19 | 2019-2025 | Resolution 360 Clip, Spyglass Discover, Apollo Esg System |
| Abbvie INC. | $852.83 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Cook Medical LLC | $640.71 | 2019-2023 | Fusion |
| Celgene Corporation | $415.24 | 2024 | Zeposia |
| Ambu INC. | $220.99 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $205.49 | 2022-2023 | Dupixent |
| Janssen Biotech, INC. | $181.68 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $174.00 | 2024-2025 | Entyvio, Gattex |
| Steris Corporation | $142.83 | 2021 | |
| Pentax of America, INC. | $125.17 | 2022 | |
| Intercept Pharmaceuticals, INC. | $116.37 | 2023 | Ocaliva |
| Endogastric Solutions, INC | $112.12 | 2019 | |
| Janssen Scientific Affairs, LLC | $103.02 | 2019 | |
| Genzyme Corporation | $99.12 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.09 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $88.78 | 2019 | |
| Shire North American Group INC | $86.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $61.23 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $28.07 | 2025 | Iqirvo |
| Qol Medical, LLC | $22.57 | 2024 | Sucraid |
| Heraeus Medical, LLC. | $12.08 | 2019 | |
| Covidien LP | $11.33 | 2020 | |
| Ucb, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silversmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.